Category: Pharmaceuticals
After COVID-19, Demand for Intravenous Solutions Shows Signs of Recovery
The COVID-19 pandemic had a negative impact on multiple industries and decreased the demand for many medical devices and pharmaceutical products. Even though the larger number of hospitalizations due ... Read More
OncoSec and Inovio Pursuing Phase 1 Clinical Trials for COVID-19 Vaccine
OncoSec and Inovio Pharmaceuticals have announced they are testing potential COVID-19 vaccines and pursuing first-in-human Phase 1 clinical trials. As of April 9, the FDA has not approved any preventa... Read More
Coronavirus and Ibuprofen: Is it safe to take?
Coronavirus and Ibuprofen: Is it safe to take? Medical professionals no longer recommend using ibuprofen to manage coronavirus symptoms. The health minister of France, Olivier Véran has warned citize... Read More
AbbVie Announces International Skyrizi Approval
Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The Japan Ministry of Health, Labour and Welfare has recently approved AbbVie’s Skyrizi for trea... Read More
Trial Finds Heightened Blood Clot Risk with High Xeljanz Doses, FDA Alerts
Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The United States Food and Drug Administration (FDA) has recently issued an alert regarding Xeljan... Read More
Janssen Submits Application To U.S. FDA Seeking Approval Of STELARA® (ustekinumab) For Treatment Of Moderately To Severely Active Ulcerative Colitis
Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supple... Read More
Medicare Coverage Changes Could Significantly Impact Biosimilar Adoption
Register to receive a free Global Immunology Drugs Market report synopsis and brochure By Kamran Zamanian and Jacqueline Ding, iData Research Inc. The United States is still an emerging market for bi... Read More
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure Eli Lilly and Company announced Taltz® (ixekizumab) met the primary and all major sec... Read More
